Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Cappelli

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Rheumatology and Therapy|October 19, 2023
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid ArthritisLaura C Cappelli, George Reed, Dimitrios A Pappas, et al.
ACR Open Rheumatology|December 7, 2023
Anti-Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid ArthritisLaura C Cappelli, David Hines, Hong Wang, et al.
Arthritis Care & Research|December 21, 2016
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the LiteratureLaura C Cappelli, Anna Kristina Gutierrez, Clifton O Bingham, et al.
Rheumatic Diseases Clinics of North America|April 26, 2024
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to ManagementNamrata Singh, Anupama Shahane, Jeffrey A Sparks, et al.
Rheumatology (Oxford, England)|August 30, 2023
Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Omer Kamal, Michelle Jones, et al.
RMD Open|June 7, 2019
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literatureCassandra Calabrese, Laura C Cappelli, Marie Kostine, et al.
Arthritis Research & Therapy|March 24, 2018
Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritisLaura C Cappelli, Maximilian F Konig, Allan C Gelber, et al.
Immunological Reviews|January 14, 2020
Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritisLaura C Cappelli, Mekha A Thomas, Clifton O Bingham, et al.
Rheumatology (Oxford, England)|December 4, 2018
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Mehmet T Dorak, Maria P Bettinotti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2018
Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid ArthritisErika Darrah, Fang Yu, Laura C Cappelli, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Rheumatology and Therapy|October 19, 2023
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid ArthritisLaura C Cappelli, George Reed, Dimitrios A Pappas, et al.
ACR Open Rheumatology|December 7, 2023
Anti-Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid ArthritisLaura C Cappelli, David Hines, Hong Wang, et al.
Arthritis Care & Research|December 21, 2016
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the LiteratureLaura C Cappelli, Anna Kristina Gutierrez, Clifton O Bingham, et al.
Rheumatic Diseases Clinics of North America|April 26, 2024
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to ManagementNamrata Singh, Anupama Shahane, Jeffrey A Sparks, et al.
Rheumatology (Oxford, England)|August 30, 2023
Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Omer Kamal, Michelle Jones, et al.
RMD Open|June 7, 2019
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literatureCassandra Calabrese, Laura C Cappelli, Marie Kostine, et al.
Arthritis Research & Therapy|March 24, 2018
Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritisLaura C Cappelli, Maximilian F Konig, Allan C Gelber, et al.
Immunological Reviews|January 14, 2020
Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritisLaura C Cappelli, Mekha A Thomas, Clifton O Bingham, et al.
Rheumatology (Oxford, England)|December 4, 2018
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Mehmet T Dorak, Maria P Bettinotti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2018
Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid ArthritisErika Darrah, Fang Yu, Laura C Cappelli, et al.
Pageof 6